MMWR Morb Mortal Wkly RepMMWR Morb. Mortal. Wkly. RepWRMorbidity and Mortality Weekly Report0149-21951545-861XCenters for Disease Control and Prevention6478056mm6811a210.15585/mmwr.mm6811a2Full ReportTuberculosis — United States, 2018TalwarAmishMD12TsangClarisse A.MPH1PriceSandy F.1PrattRobert H.1WalkerWilliam L.DVMPhD1SchmitKristine M.MD1LangerAdam J.DVM11Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; 2Epidemic Intelligence Service, CDC.Corresponding author: Amish Talwar, atalwar@cdc.gov, 404-718-7207.223201922320196811257262All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
In 2018, a total of 9,029 new tuberculosis (TB) cases were reported in the United States, representing a 0.7% decrease from 2017.* The U.S. TB incidence in 2018 (2.8 per 100,000 persons) represented a 1.3% decrease from 2017; the rate among non–U.S.-born persons was >14 times that in U.S.-born persons. This report summarizes provisional TB surveillance data reported to CDC’s National Tuberculosis Surveillance System (NTSS) through 2018. Although the total number of cases and incidence are the lowest ever reported in the United States, a recent model predicted that the U.S. TB elimination goal (annual incidence of <1 case per 1 million persons) will not be attained in the 21st century without greatly increased investment in detection and treatment of latent TB infection (LTBI) (1). Programs to identify, test, and treat populations at high risk for TB remain important to eliminating TB in the United States.
Health departments in the 50 states and District of Columbia (DC) electronically report provisional case data that meet the national TB surveillance case definition to CDC.† Data reported include demographic information (e.g., birth date, sex, self-reported race/ethnicity, and country of birth), clinical information (e.g., reason for TB evaluation, anatomic site of disease, test results, and therapy administered), and information on TB risk factors (e.g., human immunodeficiency virus [HIV] infection status, history of homelessness, and residence in a congregate setting). According to U.S. Census Bureau definitions, a “U.S.-born” person is classified as one born in the United States or a U.S. territory or born abroad to a U.S. citizen parent. Race/ethnicity data are collected and reported using federal classification standards; Hispanics/Latinos can be of any race, and all other reported race categories are non-Hispanic/Latino. CDC derived the denominators used to calculate national and state TB incidence from July 2018 U.S. Census Bureau population estimates (2) and the denominators used to calculate TB incidence by national origin and race/ethnicity from July 2018 Current Population Survey data (3). The number of reported TB cases and TB incidence (cases per 100,000 persons) for 2017 and 2018, as well as the percent changes from 2017 to 2018, were calculated for the 50 states and DC and for each U.S. Census Bureau division. The numbers of TB cases and TB incidence per 100,000 persons were calculated by national origin and race/ethnicity for 2015–2018.
TB incidence declined 1.3% from 2017 to 2018 and an average of 1.6% per year during the last 4 years (2014–2018), a slower pace of decline than the 4.7% annual decline during 2010–2014.§ State-specific TB incidence for 2018 ranged from 0.2 per 100,000 in Wyoming to 8.5 in Alaska, with a median rate of 1.9 (Table 1). Ten states (Alaska, California, Florida, Hawaii, Maryland, Massachusetts, Minnesota, New Jersey, New York, and Texas) and DC reported TB incidence above the national rate. As has been the case for over 2 decades, four states (California, Florida, New York, and Texas) accounted for approximately half of the reported cases of TB in the United States.
Tuberculosis (TB) case counts and incidence with annual percent changes, by U.S. Census division and state/district — 50 states and the District of Columbia, 2017 and 2018
Census division/State
No. of reported TB cases*
TB incidence†
2017
2018
% Change
2017
2018
% Change§
Division 1: New England
Connecticut
63
51
−19.0
1.8
1.4
−19.0
Maine
14
14
0.0
1.0
1.0
−0.2
Massachusetts
209
200
−4.3
3.0
2.9
−4.8
New Hampshire
19
12
−36.8
1.4
0.9
−37.2
Rhode Island
13
20
53.8
1.2
1.9
53.7
Vermont
3
5
66.7
0.5
0.8
66.2
Total
321
302
−5.9
2.2
2.0
−6.2
Division 2: Middle Atlantic
New Jersey
283
290
2.5
3.2
3.3
2.2
New York
800
750
−6.3
4.1
3.8
−6.0
Pennsylvania
192
212
10.4
1.5
1.7
10.3
Total
1,275
1,252
−1.8
3.1
3.0
−1.8
Division 3: East North Central
Illinois
335
319
−4.8
2.6
2.5
−4.4
Indiana
100
116
16.0
1.5
1.7
15.4
Michigan
133
109
−18.0
1.3
1.1
−18.2
Ohio
149
178
19.5
1.3
1.5
19.2
Wisconsin
49
49
0.0
0.8
0.8
−0.4
Total
766
771
0.7
1.6
1.6
0.5
Division 4: West North Central
Iowa
47
49
4.3
1.5
1.6
3.8
Kansas
29
28
−3.4
1.0
1.0
−3.5
Minnesota
178
172
−3.4
3.2
3.1
−4.1
Missouri
87
82
−5.7
1.4
1.3
−6.0
Nebraska
21
27
28.6
1.1
1.4
27.8
North Dakota
14
13
−7.1
1.9
1.7
−7.7
South Dakota
14
12
−14.3
1.6
1.4
−15.2
Total
390
383
−1.8
1.8
1.8
−2.3
Division 5: South Atlantic
Delaware
15
22
46.7
1.6
2.3
45.1
District of Columbia
36
36
0.0
5.2
5.1
−1.0
Florida
549
591
7.7
2.6
2.8
6.0
Georgia
293
273
−6.8
2.8
2.6
−7.8
Maryland
207
207
0.0
3.4
3.4
−0.3
North Carolina
213
196
−8.0
2.1
1.9
−9.0
South Carolina
101
86
−14.9
2.0
1.7
−15.9
Virginia
204
205
0.5
2.4
2.4
−0.1
West Virginia
16
7
−56.3
0.9
0.4
−56.0
Total
1,634
1,623
−0.7
2.5
2.5
−1.7
Division 6: East South Central
Alabama
120
91
−24.2
2.5
1.9
−24.4
Kentucky
65
65
0.0
1.5
1.5
−0.3
Mississippi
52
80
53.8
1.7
2.7
54.0
Tennessee
127
140
10.2
1.9
2.1
9.2
Total
364
376
3.3
1.9
2.0
2.8
Division 7: West South Central
Arkansas
85
79
−7.1
2.8
2.6
−7.4
Louisiana
141
105
−25.5
3.0
2.3
−25.4
Oklahoma
54
74
37.0
1.4
1.9
36.7
Texas
1,127
1,129
0.2
4.0
3.9
−1.1
Total
1,407
1,387
−1.4
3.5
3.4
−2.4
Division 8: Mountain
Arizona
188
178
−5.3
2.7
2.5
−6.9
Colorado
84
64
−23.8
1.5
1.1
−24.9
Idaho
10
15
50.0
0.6
0.9
47.0
Montana
3
5
66.7
0.3
0.5
65.2
Nevada
80
69
−13.8
2.7
2.3
−15.5
New Mexico
37
41
10.8
1.8
2.0
10.7
Utah
29
18
−37.9
0.9
0.6
−39.1
Wyoming
2
1
−50.0
0.3
0.2
−49.9
Total
433
391
−9.7
1.8
1.6
−11.1
Division 9: Pacific
Alaska
53
63
18.9
7.2
8.5
19.2
California
2,059
2,091
1.6
5.2
5.3
1.1
Hawaii
116
120
3.4
8.1
8.4
3.7
Oregon
69
81
17.4
1.7
1.9
16.2
Washington
207
189
−8.7
2.8
2.5
−10.0
Total
2,504
2,544
1.6
4.7
4.8
1.0
United States
9,094
9,029
−0.7
2.8
2.8
−1.3
* Case counts were based on data from the National Tuberculosis Surveillance System as of February 11, 2019.
† Cases per 100,000 persons. TB incidence was calculated using denominators from U.S. Census Bureau midyear population estimates.
§ Percentage change in incidence was calculated using unrounded rate for 2017 and 2018.
Among the 9,029 TB cases reported in the United States in 2018, approximately two thirds (6,276 [69.5%]) occurred in non–U.S.-born persons, whereas 2,662 (29.5%) occurred in U.S.-born persons; 91 (1.0%) cases occurred in persons for whom no national origin was documented (Table 2). This distribution is similar to that in 2017, when 6,392 (70.3%) cases occurred in non–U.S.-born persons, 2,693 (29.6%) occurred in U.S.-born persons, and 9 (0.1%) occurred in persons for whom no national origin was documented. TB incidence among non–U.S.-born persons (14.2 cases per 100,000) decreased by 3.8% from 2017 to 2018, and the incidence among U.S.-born persons (1.0 cases per 100,000) decreased by 1.8% (Figure).¶
Newly diagnosed tuberculosis (TB) case counts and incidence,<xref ref-type="fn" rid="FN1">*</xref> by national origin and race/ethnicity — United States, 2015–2018<xref ref-type="fn" rid="FN2"><sup>†</sup></xref>
U.S. population group
No. of cases (incidence)
2015
2016
2017
2018
U.S.-born§
Hispanic
660 (1.8)
603 (1.6)
591 (1.5)
582 (1.5)
White, non-Hispanic
984 (0.5)
910 (0.5)
797 (0.4)
801 (0.4)
Black, non-Hispanic
1,142 (3.3)
1,066 (3.0)
1,008 (2.9)
938 (2.6)
Asian
138 (2.1)
146 (2.1)
134 (1.9)
139 (1.9)
American Indian/Alaska Native
144 (7.0)
110 (5.1)
92 (3.8)
102 (4.0)
Native Hawaiian/Pacific Islander
42 (6.1)
31 (4.3)
46 (6.7)
42 (5.6)
Multiple or unknown race/Ethnicity
25 (—¶)
23 (—¶)
25 (—¶)
58 (—¶)
Total U.S.-born
3,135 (1.1)
2,889 (1.0)
2,693 (1.0)
2,662 (1.0)
Non–U.S.-born
Hispanic
2,036 (10.4)
1,990 (10.1)
1,973 (10.0)
2,006 (10.1)
White, non-Hispanic
258 (3.4)
286 (3.8)
268 (3.5)
251 (3.1)
Black, non-Hispanic
858 (23.2)
914 (22.7)
901 (22.2)
829 (19.9)
Asian
3,157 (29.7)
3,051 (27.2)
3,126 (27.3)
2,993 (25.4)
American Indian/Alaska Native
1 (1.9)
1 (2.9)
2 (2.9)
3 (5.2)
Native Hawaiian/Pacific Islander
60 (18.6)
47 (13.0)
66 (22.4)
74 (25.0)
Multiple or unknown race/Ethnicity
37 (—¶)
68 (—¶)
56 (—¶)
120 (—¶)
Total non–U.S.-born
6,407 (15.3)
6,357 (14.7)
6,392 (14.7)
6,276 (14.2)
Unknown national origin
5 (—¶)
7 (—¶)
9 (—¶)
91 (—¶)
Overall total
9,547 (3.0)
9,253 (2.9)
9,094 (2.8)
9,029 (2.8)
* Incidence was calculated as cases per 100,000 persons.
† Case counts were based on data from the National Tuberculosis Surveillance System as of February 11, 2019. The Current Population Survey (https://www.census.gov/programs-surveys/cps.html) provides the population denominators used to calculate TB incidence according to national origin and racial/ethnic group.
§ U.S.-born persons were born in the United States or U.S. territories (American Samoa, Commonwealth of the Northern Mariana Islands, Guam, Puerto Rico, and U.S. Virgin Islands) or born elsewhere to a U.S. citizen. Non–U.S.-born persons were born outside the United States (or the U.S. territories), and include those born in the sovereign freely associated states (Federated States of Micronesia, Marshall Islands, and Palau) (unless one or both parents were U.S. citizens).
¶ Incidence was not calculated for these categories.
Number of tuberculosis (TB) cases and TB incidence, by national origin*,† — United States, 2010–2018
* Number of cases among non–U.S.-born and U.S.-born persons and associated incidence exclude cases with unknown country of origin. Incidence for all U.S. TB cases includes cases with unknown country of origin.
† Incidence for non–U.S.-born and U.S.-born persons calculated using population estimates from Current Population Survey. Incidence for all persons with TB diagnosed in the United States calculated using population estimates from U.S. Census Bureau.
The figure is a combination line and bar graph showing the number of tuberculosis cases and incidence of tuberculosis, by national origin, in the United States during 2010–2018.
Among non–U.S.-born persons with TB, incidence in 2018 was highest among Asians, followed by Native Hawaiians/Pacific Islanders, non-Hispanic blacks (blacks), Hispanics, and American Indian/Alaska Natives, and was lowest among non-Hispanic whites (whites) (Table 2). Among TB cases in non–U.S.-born persons, incidence decreased from 2017 to 2018 among Asians, blacks, and whites, but increased in Hispanics. The top five countries of birth of non–U.S.-born persons with TB were Mexico (1,195 cases; 19.0% of all non–U.S.-born cases), Philippines (781; 12.4%), India (616; 9.8%), Vietnam (503; 8.0%), and China (374; 6.0%). Among TB cases in non–U.S.-born persons, 2,905 (46.3%) were diagnosed ≥10 years after the patient first arrived in the United States.
The highest TB incidence for U.S.-born persons occurred among Native Hawaiians/Pacific Islanders, followed by American Indians/Alaska Natives, blacks, Asians, and Hispanics, and was lowest in whites (Table 2). Among U.S.-born persons, TB incidence decreased from 2017 to 2018 among blacks, but remained stable among Asians, Hispanics, and whites.
During 2018, 4.1% of TB cases were reported among persons who experienced homelessness within the year preceding diagnosis, 3.3% among residents of a correctional facility at the time of diagnosis, and 1.6% among residents of a long-term care facility at the time of diagnosis.** Among cases diagnosed in persons who experienced homelessness and among residents of long-term care facilities, 60.8% and 56.8%, respectively, were in persons who were U.S.-born, whereas among residents of a correctional facility, only 33.6% were U.S.-born. HIV status was known for 85.3% of TB cases reported in 2018. Overall, 5.3% of TB patients with known HIV status were coinfected with HIV, including 8.6% among persons aged 25–44 years.
Initial drug-susceptibility testing for at least isoniazid and rifampin was performed for 73.5% of all TB cases (and 93.8% of culture-confirmed cases) in 2017, the most recent year for which complete data are available.†† Among the 6,684 TB cases reported in 2017 with available drug-susceptibility testing results, 128 (1.9%) were multidrug-resistant TB.§§ Of these multidrug-resistant TB cases, 110 (85.9%) were in non–U.S.-born persons; 26 (20.3%) multidrug-resistant TB patients reported a previous episode of TB. Three cases of extensively drug-resistant TB¶¶ were reported, all of which occurred in non–U.S.-born persons.
Discussion
In 2018, the provisional TB case count and incidence for the United States declined slightly, compared with those in 2017. Lower counts and incidences were seen in U.S.-born persons as well as in non–U.S.-born persons, who continue to represent a large majority of TB cases and have an incidence >14 times that of U.S.-born persons.
In 2018, approximately half (46.3%) of TB cases in non–U.S.-born persons received a TB diagnosis ≥10 years after first arriving in the United States, consistent with a published estimate that reactivation of remotely acquired LTBI has been responsible for >80% of domestic TB cases (4). Therefore, TB elimination will require a concerted effort to enhance surveillance, detection, and treatment for LTBI among populations at increased risk.
Between 3.1% and 5.0% of the U.S. population has LTBI (5,6). Without treatment, 5%–10% of persons with LTBI will develop TB disease in their lifetime (7). CDC and the U.S. Preventive Services Task Force recommend testing populations that are at increased risk for TB, including persons born in or who frequently travel to countries where TB is prevalent and persons who currently live, or previously lived, in congregate settings. CDC also recommends testing for TB in health care workers and others who work in places where there is a high risk of TB transmission, persons who are contacts of a person with infectious TB disease, and immunocompromised persons, who have a higher risk for developing TB disease once infected (8). According to one model, increased uptake of LTBI screening and treatment among populations at higher risk for TB would result in an incidence of 26 new infections per million by 2050 (1). Detection of LTBI can be improved by the preferential use of interferon-γ release assays over the tuberculin skin test, especially in persons with a history of Bacillus Calmette-Guérin vaccination or who are unlikely to return to have their tuberculin skin test read (9). In addition, the adoption of shorter, safer, and more convenient LTBI treatment regimens continues to be critical in improving treatment initiation and completion (10). Therefore, CDC recommends either 3 months of once-weekly rifapentine plus isoniazid or 4 months of daily rifampin for treatment of LTBI; these regimens may be used instead of longer courses of isoniazid alone (10). Given that the estimated prevalence of LTBI is higher among non–U.S.-born persons (6) and that rates of TB disease are much higher in this group, the detection and treatment of LTBI among non–U.S.-born persons should be prioritized. CDC is working with its state and local partners to develop an LTBI surveillance system to track effectiveness of public health measures to address LTBI.
The findings in this report are subject to at least two limitations. First, this analysis is limited to the reported provisional number of TB cases and incidence for 2018. Second, incidences are calculated using estimated population numbers as denominators.***
TB case counts and incidence in the United States in 2018 are the lowest ever reported, but this progress has slowed recently. To achieve TB elimination, the United States must expand detection and treatment of LTBI and TB disease. TB is a global problem, and its elimination will depend on cooperative measures to detect and treat LTBI and TB disease around the world.
Summary
What is already known about this topic?
The number of tuberculosis (TB) cases and incidence in the United States have steadily declined since 1993.
What is added by this report?
U.S. TB incidence in 2018 (2.8 cases per 100,000 persons) was the lowest ever reported. Non–U.S.-born persons accounted for approximately two thirds of cases.
What are the implications for public health practice?
The current decline in TB incidence is insufficient to eliminate TB in the United States in the 21st century. TB elimination will require enhanced surveillance, detection, and treatment. Focusing on populations that are at increased risk for latent TB infection will be important in achieving TB elimination.
Acknowledgments
State, local, and territorial health department personnel; Cynthia Adams, Stacey Parker, Jeanette Roberts, Katrina Williams, CDC Information Management Services; Rebekah Stewart, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.
This report is limited to National Tuberculosis Surveillance System provisional data as of February 11, 2019. Updated data will be available in CDC’s annual TB surveillance report later this year.
These calculations are based on unrounded annual TB incidence rates.
The decrease in overall incidence does not fall within the range of decreases by national origin because, although the denominators used to calculate both rates increased from 2017 to 2018, the denominator used for rates by national origin (according to Current Population Survey data) increased by an additional 705,000 persons, compared with the denominator used to calculate the overall rate (according to U.S. Census Bureau data). This resulted in a larger calculated decrease in rate by national origin, compared with the overall rate.
Percentages are calculated using cases with complete data for each of these three individual variables.
Because information on initial drug-susceptibility testing for isoniazid and rifampin is only available for 66.5% of all TB cases in 2018 (and 86.1% of culture-confirmed cases), more complete data from 2017 are presented instead. Culture-confirmed cases are defined as cases that were culture-positive on a specimen collected within 2 weeks of start of TB treatment.
A case of TB caused by a strain of Mycobacterium tuberculosis that is resistant to at least isoniazid and rifampin.
A case of TB caused by a strain of Mycobacterium tuberculosis that is resistant to isoniazid and rifampin as well as any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).
The second and third references provide information on population estimates used to calculate denominators.
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
ReferencesMenziesNA, CohenT, HillAN, Prospects for tuberculosis elimination in the United States: results of a transmission dynamic model.Am J Epidemiol2018;187:2011–20. 10.1093/aje/kwy09429762657US Census Bureau. National population totals and components of change: 2010–2018. Washington, DC: US Census Bureau; 2018https://www.census.gov/data/datasets/time-series/demo/popest/2010s-national-total.htmlUS Census Bureau. TheDataWeb. Washington, DC: US Census Bureau; 2018https://dataferrett.census.govYuenCM, KammererJS, MarksK, NavinTR, FranceAM. Recent transmission of tuberculosis—United States, 2011–2014.PLoS One2016;11:e0153728. 10.1371/journal.pone.015372827082644HaddadMB, RazKM, LashTL, Simple estimates for local prevalence of latent tuberculosis infection, United States, 2011–2015.Emerg Infect Dis2018;24:1930–3. 10.3201/eid2410.18071630226174MiramontesR, HillAN, Yelk WoodruffRS, Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011–2012.PLoS One2015;10:e0140881. 10.1371/journal.pone.014088126536035CDC. The difference between latent TB infection and TB disease. Atlanta, GA: US Department of Health and Human Services, CDC; 2014https://www.cdc.gov/tb/publications/factsheets/general/ltbiandactivetb.htmCDC. Latent TB infection testing and treatment: summary of U.S. recommendations. Atlanta, GA: US Department of Health and Human Services, CDC; 2019https://www.cdc.gov/tb/publications/ltbi/pdf/CDC-USPSTF-LTBI-Testing-Treatment-Recommendations-508.pdfLewinsohnDM, LeonardMK, LoBuePA, Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children.Clin Infect Dis2017;64:111–5. 10.1093/cid/ciw77828052967CDC. Treatment regimens for latent TB infection (LTBI). Atlanta, GA: US Department of Health and Human Services, CDC; 2016https://www.cdc.gov/tb/topic/treatment/ltbi.htm